Abstract: The present disclosure is generally directed to the use of antibodies that specifically bind one or more epitopes within a sortilin protein, e.g., human sortilin or mammalian sortilin, for treating and/or delaying progression of a disease, disorder, or injury in an individual in need thereof.

Abstract: A matching circuit, a radio frequency front-end power amplification circuit, and a mobile communication device are provided. The matching circuit is configurable for the radio frequency front-end power amplification circuit, including a first impedance matcher, a first bandpass filter, a first wave trap, and a first matching unit. An impedance of the first impedance matcher is a first preset impedance at a first frequency, the first bandpass filter is bridged between a front end of the first impedance matcher and ground, the first bandpass filter enables a signal of the first frequency to pass through, and suppresses at least one of a signal of a second frequency and a signal of third harmonic generation of the first frequency. The second frequency is lower than the first frequency. The first wave trap is bridged between a rear end of the first impedance matcher and the ground.

Abstract: A compressor (200), comprising: a first rotor (20) being rotatable around a first axis (11), the first rotor (20) comprising a first portion (22) and a second portion (24); and a first shaft (10) carrying the first portion (22) and the second portion (24), the first shaft (10) having a first end (12) and a second end (14) that are oppositely arranged, wherein the first rotor (20) is configured to be applied with a preset acting force in a direction from the first end (12) toward the second end (14) or from the second end (14) toward the first end (12) during rotation. The size of the compressor (200) can be reduced with the displacement of the compressor (200) remaining substantially unchanged.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Embodiments of this application disclose a video switching method and a related device, and are applied to the multimedia field. The method in embodiments of this application includes: A video transmit end receives a video switching instruction when sending a first video frame, where the first video frame is one frame of video data of a first video stream that is being sent by the video transmit end; and the video transmit end switches video data in response to the video switching instruction when a first field blanking period after the first video frame arrives. In embodiments of this application, a video data switching process of the video transmit end may be controlled to occur in the field blanking period, and the video transmit end always sends a complete video frame to a video receive end.

Abstract: This application provides a transmission method, apparatus, and system, to implement bidirectional transmission of an audio/video signal between peer devices. The transmission system may include a first transmission apparatus and a second transmission apparatus, where the first transmission apparatus is connected to the second transmission apparatus through a first cable, and the first cable includes a first number of main downlink lanes and a second number of main uplink lanes. Bidirectional transmission of the audio/video signal between the first transmission apparatus and the second transmission apparatus is performed through the first cable.

Abstract: A matching circuit, a radio frequency front-end power amplification circuit, and a mobile communication device are provided. The matching circuit is configurable for the radio frequency front-end power amplification circuit, including a first impedance matcher, a first bandpass filter, a first wave trap, and a first matching unit. An impedance of the first impedance matcher is a first preset impedance at a first frequency, the first bandpass filter is bridged between a front end of the first impedance matcher and ground, the first bandpass filter enables a signal of the first frequency to pass through, and suppresses at least one of a signal of a second frequency and a signal of third harmonic generation of the first frequency. The second frequency is lower than the first frequency. The first wave trap is bridged between a rear end of the first impedance matcher and the ground.

Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.

Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.

Abstract: Ozone generating machine for generating ozone in a ship, including: an ozone generator (OG), a liquid cooling circuit portion, a frame, comprising a base (B) for laying on the ground, a top subframe (TSF) supporting the ozone generator (OG), and at least one pair of pillars (P) arranged between the base (B) and the top subframe (TSF), characterized in that the frame comprises: at least one pair of cross-brace beams (CB), for linking the pillars (P) and a plurality of dampers (D) attached to a bottom of the base (8).

Abstract: An embodiment provides a packet transmission method and apparatus, to resolve a problem that occurs when a packet cannot traverse a NAT device when VTEPs communicate with each other through the NAT device. The method is applied to a VXLAN including a first VTEP, a second VTEP, and a NAT device. The method includes: performing, by the first VTEP, VXLAN encapsulation on a first packet, obtaining a second packet; sending, by the first VTEP, the second packet to the second VTEP through the NAT device; and performing, by the second VTEP, VXLAN decapsulation on the received second packet, to obtain the first packet. The first packet is a packet to be sent by the first VTEP, a destination port number of the second packet is obtained based on a destination IP address of the second packet, and a source port number of the second packet is a preset port number.

Abstract: A circuit structure for improving the harmonic suppression capability of a radio frequency power amplifier includes an output stage unit, a high-order harmonic suppression unit, and a low-order harmonic suppression unit. The output stage unit outputs a signal to be subjected to harmonic suppression; the high-order harmonic suppression unit comprises a first filter capacitor and a back hole, and is used for suppressing fifth or higher harmonics; the output stage unit and the first filter capacitor are connected to the ground in series by means of the back hole; the low-order harmonic suppression unit is connected to the output stage unit to suppress second, third and fourth harmonics. According to the design, the high-harmonic suppression capability of the radio frequency power amplifier is improved.

Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Abstract: An apparatus for use in a high-definition media interface (HDMI) source device includes an HDMI interface for transmitting video data and metadata to a sink device. The apparatus is configured to encode the metadata in an auxiliary video information (AVI) information frame (InfoFrame). The apparatus is further configured to transmit the AVI InfoFrame during a frame synchronous transmission window (FSTW) of the video data, wherein the FSTW begins during a video blanking interval (VBI) of the video data, on a first video blank pixel that immediately follows a last active video pixel of a preceding video frame or video field and ends a predetermined number of video lines after a start of the VBI.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.